The Active Pharmaceutical Ingredient (API) business of Arevipharma at their Radebeul site will be extended by innovation and investments, with strategic focus on outstanding quality, customer service as well as secured supplies and supply chains
Radebeul, Germany – by 1st of January 2021 the acquisition of Arevipharma by Yonsung Group was closed successfully. Arevipharma is an international and well-established production site with a long history of almost 150 years. The former AWD (Arzneimittelwerk Dresden) API site belonged to ATHOS KG since 2007. ATHOS KG is the family office of Strüngmann brothers (Dr. Andreas & Dr. Thomas Strüngmann) who supported Arevipharma to become an independent API company after divestment from Hexal group and Novartis.
Arevipharma and Yonsung will benefit from broad synergies arising from the merger of R&D-driven Yonsung Group focused on sustainable investments and the broad and well-established industry network of Arevipharma. The Radebeul site shall become the hub of European and American API business of both companies with outstanding quality , customer focus as well as secured supply chains through backward integrated production. Furthermore, Yonsung will represent and develop Arevipharma portfolio in Asian markets. The upcoming German-Korean cooperation will continue the robust growth strategy of Yonsung Group while the merger of both companies will grant the opportunity to mutually intensify the market presence and become a visible alternative to Chinese and Indian suppliers and send an important signal to secure important pharmaceutical supplies.
Yonsung will invest in renewal of the site and establish new production lines in the short term. By acquisition of Arevipharma, Yonsung Group will grow to 400 employees offering broad technology and manufacturing capabilities at five sites. Beside mutual proprietary R&D projects, both companies will focus on the important contract manufacturing business. Additionally, by development of own platform technologies for finished dosage forms, the Yonsung group has started its strategy of forward integration into a fully integrated pharmaceutical company.
Yonsung Fine Chemicals Co. Ltd. was founded in 2000 as spin-off of Sungkyunkwan University in Seoul. Prof. Won-Hun Ham and the other founders are still active in the management of the company group. Yonsung is one of the world leading suppliers of the product group of Prostaglandins and is focused on highly potent substances. Beside API, Yonsung has started to develop own FDF. Yonsung group has grown organically through proprietary development projects and patents by over 100% within the last 3 years with a turnover of more than 50 Million USD in 2020.
Arevipharma is a midsize German company, manufacturing API and intermediates with a long history at the Radebeul site since 1874 with foundation of former “Chemische Fabrik von Heyden”. Today Arevipharma is focused on production of generic and originator API, contract manufacturing of high-quality intermediate and final products according to customer specific requirements as well as R&D services. More than 30 API are part of Arevipharma portfolio for various therapeutical areas in human and veterinary medicine with a strong focus on narcotic substances. The Radebeul site offers manufacturing capabilities from gram to multi-ton scale for customers worldwide.